 SAN MATEO, Calif. and CAMBRIDGE, Mass., March 10, 2021 GLOBE NEWSWIRE -- Kronos Bio, Inc. Nasdaq: KRON, a company dedicated to transforming the lives of those affected by cancer, today announced that data from a pre-clinical study of KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 CDK9 inhibitor being developed to treat MYC-amplified solid tumors, will be presented in a poster session at the American Association for Cancer Research AACR Annual Meeting 2021, which is being held virtually April 10-15. 